Vaccinomics--the application of genomics and bioinformatics to vaccine development--is bringing a fresh approach to the Herculean problem of making vaccines against the various HIV-1 subtypes, or ...

Developing AAV capsids with improved yield, or fitness, is a key strategy for reducing manufacturing costs in order to make gene therapies more affordable. Christian Mueller and coauthors from ...

That deal is worth $35 million per year in average annual salary, but he reportedly could have gotten an even bigger deal in AAV from the Baltimore Orioles. Roch Kubatko of MASN reported that the ...

When Robert Atchison and his colleagues at the University of Pittsburgh first stumbled across adeno-associated viruses (AAV) in 1965, they initially supposed they were merely defective byproducts ...

For central nervous system (CNS) applications, attempts are being made to deliver AAV gene therapy directly to the brain parenchyma or the cerebrospinal fluid (CSF) space by intra-cisterna magna ...

Adeno-associated virus (AAV) gene therapies hold great promise, but ensuring product quality is critical. One major challenge? The presence of empty capsids, which can reduce therapeutic effectiveness ...

This in silico approach aims to increase the fitness of clinical adeno-associated virus (AAV) capsids to make gene therapies more economically viable for patients. Developing AAV capsids with ...